Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Nayak, 2012, Epidemiology of brain metastases, Curr Oncol Rep, 14, 48, 10.1007/s11912-011-0203-y Iuchi, 2013, Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma, Lung Cancer, 82, 282, 10.1016/j.lungcan.2013.08.016 Russo, 2015, A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives, Oncotarget, 6, 26814, 10.18632/oncotarget.4254 Chen, 2016, First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma, Cancer Sci, 107, 1800, 10.1111/cas.13079 Doherty, 2017, Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer, Radiother Oncol, 132, 195, 10.1016/j.radonc.2017.03.007 Heon, 2012, The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations, Clin Cancer Res, 18, 4406, 10.1158/1078-0432.CCR-12-0357 Soria, 2013, Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer, Ann Oncol, 24, 20, 10.1093/annonc/mds590 Besse, 2015, Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study, Clin Cancer Res, 21, 1896, 10.1158/1078-0432.CCR-14-2082 Ilhan-Mutlu, 2016, Bevacizumab prevents brain metastases formation in lung adenocarcinoma, Mol Cancer Ther, 15, 702, 10.1158/1535-7163.MCT-15-0582 Fu, 2016, Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer, J Chemother, 28, 218 Seto, 2014, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, 15, 1236, 10.1016/S1470-2045(14)70381-X Ouzounova, 2017, Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade, Nat Commun, 8, 14979, 10.1038/ncomms14979 Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150 Gabrilovich, 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 2, 1096, 10.1038/nm1096-1096 Horikawa, 2017, Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells, Clin Cancer Res, 23, 587, 10.1158/1078-0432.CCR-16-0387 Feng, 2012, CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer, Am J Respir Crit Care Med, 186, 1025, 10.1164/rccm.201204-0636OC Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat Rev Immunol, 9, 162, 10.1038/nri2506 Liu, 2013, Premetastatic soil and prevention of breast cancer brain metastasis, Neuro Oncol, 15, 891, 10.1093/neuonc/not031 Wang, 2017, CXCL1 is critical for pre-metastatic niche formation and metastasis in colorectal cancer, Cancer Res, 77, 3655, 10.1158/0008-5472.CAN-16-3199 Shojaei, 2007, Bv8 regulates myeloid-cell-dependent tumour angiogenesis, Nature, 450, 825, 10.1038/nature06348 Yang, 2004, Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis, Cancer Cell, 6, 409, 10.1016/j.ccr.2004.08.031 Graeber, 2002, Microglia in brain tumors, Glia, 40, 252, 10.1002/glia.10147 Hambardzumyan, 2016, The role of microglia and macrophages in glioma maintenance and progression, Nat Neurosci, 19, 20, 10.1038/nn.4185 Kusmartsev, 2008, Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma, J Immunol, 181, 346, 10.4049/jimmunol.181.1.346 Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, 12, 298, 10.1038/nrc3245 Martino, 2016, Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients, Cell Death Discov, 2, 16025, 10.1038/cddiscovery.2016.25 Wallin, 2016, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, Nat Commun, 7, 12624, 10.1038/ncomms12624